JP2006523440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006523440A5 JP2006523440A5 JP2006504100A JP2006504100A JP2006523440A5 JP 2006523440 A5 JP2006523440 A5 JP 2006523440A5 JP 2006504100 A JP2006504100 A JP 2006504100A JP 2006504100 A JP2006504100 A JP 2006504100A JP 2006523440 A5 JP2006523440 A5 JP 2006523440A5
- Authority
- JP
- Japan
- Prior art keywords
- hfe2a
- polypeptide
- isolated polynucleotide
- cell
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 76
- 101000756823 Homo sapiens Hemojuvelin Proteins 0.000 claims description 57
- 201000000386 hemochromatosis type 2A Diseases 0.000 claims description 55
- 102100022816 Hemojuvelin Human genes 0.000 claims description 54
- 230000014509 gene expression Effects 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 22
- 108700008625 Reporter Genes Proteins 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims 48
- 108091033319 polynucleotide Proteins 0.000 claims 33
- 102000040430 polynucleotide Human genes 0.000 claims 33
- 239000002157 polynucleotide Substances 0.000 claims 33
- 210000004027 cell Anatomy 0.000 claims 24
- 201000010099 disease Diseases 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 239000007857 degradation product Substances 0.000 claims 14
- 230000000694 effects Effects 0.000 claims 14
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 8
- 230000010438 iron metabolism Effects 0.000 claims 7
- 239000012472 biological sample Substances 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 208000016286 Iron metabolism disease Diseases 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 201000000361 Hemochromatosis type 2 Diseases 0.000 claims 4
- 208000007502 anemia Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 208000017667 Chronic Disease Diseases 0.000 claims 3
- 208000018565 Hemochromatosis Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 210000004969 inflammatory cell Anatomy 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 210000005229 liver cell Anatomy 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 210000002363 skeletal muscle cell Anatomy 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010022971 Iron Deficiencies Diseases 0.000 claims 1
- 206010065973 Iron Overload Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241000097929 Porphyria Species 0.000 claims 1
- 208000010642 Porphyrias Diseases 0.000 claims 1
- 208000031306 Rare hereditary hemochromatosis Diseases 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46286703P | 2003-04-15 | 2003-04-15 | |
| US48860703P | 2003-07-18 | 2003-07-18 | |
| US49845803P | 2003-08-28 | 2003-08-28 | |
| PCT/CA2004/000522 WO2004092405A2 (en) | 2003-04-15 | 2004-04-08 | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006523440A JP2006523440A (ja) | 2006-10-19 |
| JP2006523440A5 true JP2006523440A5 (enExample) | 2007-05-24 |
Family
ID=33303911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504100A Pending JP2006523440A (ja) | 2003-04-15 | 2004-04-08 | 若年性ヘモクロマトーシス遺伝子（ｈｆｅ２ａ）、その発現産物および使用法 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US20070166711A1 (enExample) |
| EP (2) | EP2006298A3 (enExample) |
| JP (1) | JP2006523440A (enExample) |
| AU (2) | AU2004231122B2 (enExample) |
| CA (1) | CA2522680A1 (enExample) |
| WO (1) | WO2004092405A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1355666B1 (en) | 2000-12-22 | 2012-06-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (RGM) and its modulators |
| AU2003234136A1 (en) | 2002-04-18 | 2003-11-03 | The General Hospital Corporation | Drg11-responsive (dragon) gene family |
| CA2522680A1 (en) | 2003-04-15 | 2004-10-28 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
| WO2006008182A1 (en) * | 2004-07-23 | 2006-01-26 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | RGMc MODIFIED TRANSGENIC ANIMALS |
| EP2954903A1 (en) * | 2005-02-16 | 2015-12-16 | The General Hospital Corporation | Use of bmp antagonists to regulate hepcidin-mediated iron metabolism |
| US7534764B2 (en) | 2005-06-29 | 2009-05-19 | The Regents Of The University Of California | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
| CA2624562A1 (en) | 2005-09-30 | 2007-04-12 | Abbott Gmbh & Co. Kg | Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use |
| WO2008079877A2 (en) * | 2006-12-22 | 2008-07-03 | Xenon Pharmaceuticals Inc. | Compositions and methods for the diagnosis and treatment of iron-related disorders |
| MX2009008104A (es) * | 2007-02-02 | 2009-08-07 | Amgen Inc | Hepcidina, antagonistas de hepcidina y metodos de uso. |
| US8895002B2 (en) | 2007-04-09 | 2014-11-25 | The General Hospital Corporation | Hemojuvelin fusion proteins and uses thereof |
| EP2033971A1 (de) * | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung |
| KR101666228B1 (ko) | 2007-09-28 | 2016-10-13 | 인트렉손 코포레이션 | 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도 |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| US20100068737A1 (en) * | 2008-09-16 | 2010-03-18 | University Of Tennessee Research Foundation | Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin |
| US8435941B2 (en) | 2008-12-05 | 2013-05-07 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
| SG172789A1 (en) | 2009-02-11 | 2011-08-29 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
| JP2013509170A (ja) | 2009-10-30 | 2013-03-14 | ノボザイムス バイオファーマ デーコー アクティーゼルスカブ | アルブミン変異体 |
| BR112012013734A2 (pt) | 2009-12-08 | 2017-01-10 | Abbott Gmbh & Co Kg | anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina. |
| WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
| AU2012251919B2 (en) | 2011-01-19 | 2016-12-15 | Ferrumax Pharmaceuticals, Inc. | Compositions for regulating iron homeostasis and methods of using same |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| EP2788370B1 (en) | 2011-12-09 | 2020-02-05 | The Regents of The University of California | Modified mini-hepcidin peptides and methods of using thereof |
| EP2807192B1 (en) | 2012-01-27 | 2018-04-18 | Abbvie Deutschland GmbH & Co. KG | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
| WO2013135896A1 (en) | 2012-03-16 | 2013-09-19 | Novozymes Biopharma Dk A/S | Albumin variants |
| RU2670063C2 (ru) | 2012-11-08 | 2018-10-17 | Альбумедикс А/С | Варианты альбумина |
| PL2968443T3 (pl) | 2013-03-15 | 2022-02-07 | Protagonist Therapeutics, Inc. | Analogi hepcydyny i ich zastosowania |
| CN113621027A (zh) | 2014-05-16 | 2021-11-09 | 领导医疗有限公司 | α4β7整联蛋白硫醚肽拮抗剂 |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| AU2015328002A1 (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
| US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
| JP2018508466A (ja) | 2014-12-29 | 2018-03-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｓ−アルキル化ヘプシジンペプチドならびにその作製及び使用方法 |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| EP3337816B1 (en) | 2015-08-20 | 2024-02-14 | Albumedix Ltd | Albumin variants and conjugates |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| EP3432906A4 (en) | 2016-03-23 | 2020-04-01 | Protagonist Therapeutics, Inc. | METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS |
| WO2018128828A1 (en) | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| TW201920234A (zh) | 2017-09-11 | 2019-06-01 | 美商領導醫療有限公司 | 類鴉片促效劑肽及其用途 |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP3802594A1 (en) | 2018-06-08 | 2021-04-14 | Pfizer Inc. | Methods of treating iron metabolic disease with a neutralizing antibody binding erhythroferrone |
| JP7534382B2 (ja) | 2019-07-10 | 2024-08-14 | プロタゴニスト セラピューティクス， インコーポレイテッド | インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| EP4090669A4 (en) | 2020-01-15 | 2024-11-20 | Janssen Biotech, Inc. | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES |
| CN118063554A (zh) | 2020-01-15 | 2024-05-24 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
| EP4149548A4 (en) | 2020-05-13 | 2024-05-08 | Disc Medicine, Inc. | ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS |
| EP4247403A4 (en) | 2020-11-20 | 2024-12-11 | JANSSEN Pharmaceutica NV | COMPOSITIONS OF PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR |
| AU2022311814A1 (en) | 2021-07-14 | 2024-02-29 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of interleukin-23 receptor |
| WO2023091968A1 (en) | 2021-11-17 | 2023-05-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
| WO2024170505A1 (en) | 2023-02-13 | 2024-08-22 | Institut National de la Santé et de la Recherche Médicale | Methods of treatment of iron overload associated diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU716924B2 (en) | 1994-10-27 | 2000-03-09 | Genentech Inc. | AL-1 neurotrophic factor, a ligand for an EPH related tyrosine kinase receptor |
| US5994315A (en) * | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
| US6319906B1 (en) * | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
| US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| WO2000073801A2 (en) | 1999-05-28 | 2000-12-07 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
| US6180353B1 (en) * | 2000-01-24 | 2001-01-30 | Isis Pharmaceuticals Inc. | Antisense modulation of daxx expression |
| US6800455B2 (en) * | 2000-03-31 | 2004-10-05 | Scios Inc. | Secreted factors |
| EP1355666B1 (en) * | 2000-12-22 | 2012-06-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (RGM) and its modulators |
| EP1368475A4 (en) * | 2001-03-15 | 2004-10-20 | Nuvelo Inc | NEW NUCLEIC ACIDS AND NEW POLYPEPTIDES |
| JP2003135075A (ja) * | 2001-11-05 | 2003-05-13 | Research Association For Biotechnology | 新規な全長ｃＤＮＡ |
| AU2003234136A1 (en) | 2002-04-18 | 2003-11-03 | The General Hospital Corporation | Drg11-responsive (dragon) gene family |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| CA2522680A1 (en) * | 2003-04-15 | 2004-10-28 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
| US7534764B2 (en) | 2005-06-29 | 2009-05-19 | The Regents Of The University Of California | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
-
2004
- 2004-04-08 CA CA002522680A patent/CA2522680A1/en not_active Abandoned
- 2004-04-08 EP EP08154618A patent/EP2006298A3/en not_active Withdrawn
- 2004-04-08 AU AU2004231122A patent/AU2004231122B2/en not_active Ceased
- 2004-04-08 WO PCT/CA2004/000522 patent/WO2004092405A2/en not_active Ceased
- 2004-04-08 US US10/552,158 patent/US20070166711A1/en not_active Abandoned
- 2004-04-08 EP EP04726398A patent/EP1618131A2/en not_active Withdrawn
- 2004-04-08 JP JP2006504100A patent/JP2006523440A/ja active Pending
-
2005
- 2005-08-04 US US11/197,710 patent/US7511018B2/en not_active Expired - Fee Related
-
2009
- 2009-02-09 US US12/322,931 patent/US7893206B2/en not_active Expired - Fee Related
- 2009-06-19 US US12/456,667 patent/US8080651B2/en not_active Expired - Fee Related
- 2009-09-15 US US12/584,947 patent/US20100068803A1/en not_active Abandoned
-
2010
- 2010-06-29 AU AU2010202722A patent/AU2010202722B2/en not_active Ceased
-
2011
- 2011-01-24 US US12/931,068 patent/US8252578B2/en not_active Expired - Fee Related
-
2012
- 2012-07-19 US US13/553,321 patent/US8507435B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006523440A5 (enExample) | ||
| Sun et al. | Mosaic mutant analysis identifies PDGFRα/PDGFRβ as negative regulators of adipogenesis | |
| Ziegler et al. | Insulin-like growth factor II: an essential adult stem cell niche constituent in brain and intestine | |
| Fusco et al. | Roles of HMGA proteins in cancer | |
| Ruan et al. | The multifaceted role of periostin in tumorigenesis | |
| Ongwijitwat et al. | Is nuclear respiratory factor 2 a master transcriptional coordinator for all ten nuclear-encoded cytochrome c oxidase subunits in neurons? | |
| Perry et al. | Complex regulation of acetylcholinesterase gene expression in human brain tumors | |
| Erdmann et al. | The Adenomatous Polyposis Coli-protein (APC) interacts with the protein tyrosine phosphatase PTP-BL via an alternatively spliced PDZ domain | |
| Sakata et al. | Mechanical stretch induces TGF‐β synthesis in hepatic stellate cells | |
| Lodyga et al. | XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway | |
| Hakim et al. | Modulation of TNF‐α expression in bone marrow macrophages: involvement of vitamin D response element | |
| CA2353086A1 (en) | Pgc-1, a novel brown fat ppar.gamma. coactivator | |
| Jinnin et al. | Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves Ets1 and Fli1 | |
| Chauvet et al. | Control of gene expression by the retinoic acid-related orphan receptor alpha in HepG2 human hepatoma cells | |
| Hu et al. | CCAAT/enhancer-binding protein β isoforms and the regulation of α-smooth muscle actin gene expression by IL-1β | |
| Kasprzak et al. | Role of alternatively spliced messenger RNA (mRNA) isoforms of the insulin-like growth factor 1 (IGF1) in selected human tumors | |
| Chen et al. | Int6/eIF3e silencing promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor 2α expression | |
| Yang et al. | A Zeb2-miR-200c loop controls midbrain dopaminergic neuron neurogenesis and migration | |
| Bosc et al. | Regulation of Her2/neu promoter activity by the ETS transcription factor, ER81 | |
| Miao et al. | Inhibition of high-mobility-group A2 protein binding to DNA by netropsin: a biosensor-surface plasmon resonance assay | |
| Sivko et al. | CCAAT/enhancer binding protein δ (C/EBPδ) regulation and expression in human mammary epithelial cells: II. Analysis of activating signal transduction pathways, transcriptional, post‐transcriptional, and post‐translational control | |
| Tanioka et al. | Regulation of the human leukocyte‐derived arginine aminopeptidase endoplasmic reticulum‐aminopeptidase 2 gene by interferon‐γ | |
| CN1159585C (zh) | 检测瘦素的方法 | |
| Shin et al. | Harnessing the regenerative potential of interleukin11 to enhance heart repair | |
| Scholz et al. | Oxygen-dependent gene expression in development and cancer: lessons learned from the Wilms’ tumor gene, WT1 |